Dolutegravir + lamivudine combo for HIV1

The US FDA approved dolutegravir and lamivudine (Dovato) as a complete regimen for the treatment of HIV-1 infection in adults with no antiretroviral treatment history.

This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV, ViiV Healthcare said.

The efficacy and safety of Dovato, one tablet taken daily, were demonstrated in two identical, randomized, double-blind, controlled clinical trials in 1,433 HIV-infected adults with no prior antiretroviral treatment history.

The trials showed that a drug regimen containing dolutegravir and lamivudine had a similar effect of reducing the amount of HIV in the blood compared to another drug regimen, which included dolutegravir, emtricitabine, and tenofovir.